SKCPT: Difference between revisions
Jump to navigation
Jump to search
Content deleted Content added
←Created page with ''''SKCPT''' is a drug under development by SK Chemicals for the treatment of osteoarthritis. It is in a Phase III trial as of 2023.<ref>{{cite web |url=https://www.globaldata.com/store/report/skcpt-in-osteoarthritis-loa-innovation-and-trend-analysis/ |access-date=4 November 2023}}</ref><ref>{{cite journal |last1=Kim |first1=Hye-Min |last2=Kang |first2=Minseok |last3=Jung |first3=Yoon-Seok |last4=Lee |first4=Yoon-Jung |last5=Choi |first5=Wonjae |last...' |
(No difference)
|
Revision as of 04:30, 4 November 2023
SKCPT is a drug under development by SK Chemicals for the treatment of osteoarthritis. It is in a Phase III trial as of 2023.[1][2][3]
References
- ^ https://www.globaldata.com/store/report/skcpt-in-osteoarthritis-loa-innovation-and-trend-analysis/. Retrieved 4 November 2023.
{{cite web}}: Missing or empty|title=(help) - ^ Kim, Hye-Min; Kang, Minseok; Jung, Yoon-Seok; Lee, Yoon-Jung; Choi, Wonjae; Yoo, Hunseung; Kim, JeongHoon; An, Hyo-Jin (January 2023). "Effects of SKCPT on Osteoarthritis in Beagle Meniscectomy and Cranial Cruciate Ligament Transection Models". International Journal of Molecular Sciences. 24 (19): 14972. doi:10.3390/ijms241914972. ISSN 1422-0067.
{{cite journal}}: CS1 maint: unflagged free DOI (link) - ^ "SKCPT by SK Chemicals for Osteoarthritis: Likelihood of Approval". Pharmaceutical Technology. 31 July 2023. Retrieved 4 November 2023.